| Kristine Angelo, LMFT | |
|
1034 S Brentwood Blvd Ste 555, Richmond Heights, MO 63117-1265 | |
| (314) 394-8757 | |
| Not Available |
| Full Name | Kristine Angelo |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 1034 S Brentwood Blvd Ste 555, Richmond Heights, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821383175 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 2011003480 (Missouri) | Secondary |
| 106H00000X | Marriage & Family Therapist | 0000000839 (Tennessee) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kristine Angelo, LMFT 1034 S Brentwood Blvd Ste 555, Richmond Heights, MO 63117-1265 Ph: (314) 394-8757 | Kristine Angelo, LMFT 1034 S Brentwood Blvd Ste 555, Richmond Heights, MO 63117-1265 Ph: (314) 394-8757 |
News Archive
BD (Becton, Dickinson and Company) today reported quarterly revenues of $1.898 billion for the fourth fiscal quarter ended September 30, 2009, representing an increase of 5 percent from the prior-year period, or 8 percent excluding the unfavorable impact from foreign currency translation.
According to the World Health Organization (WHO), COVID-19 long-haulers are people who experience symptoms such as body ache, fatigue, shortness of breath, headache, difficulty concentrating, loss of taste or smell, or other health issues long after they test negative for the virus. It can be defined as having serious and prolonged symptoms three months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
The American Society for Radiation Oncology and the American Urological Association today announced updates to their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy in patients with and without evidence of prostate cancer recurrence to include new published research related to adjuvant radiotherapy.
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.
› Verified 3 days ago